Related Experiment Video
Updated: May 7, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
Edaravone for acute stroke: Meta-analyses of data from randomized controlled trials
Jie Yang1,2, Xiaoyang Cui1, Jie Li1,3
1a Department of Neurology , West China Hospital, Sichuan University , Chengdu , PR China .
Aims:
To assess the effectiveness of edaravone for acute stroke including ischemic stroke and intracerebral hemorrhage (ICH).
Methods:
We identified randomized controlled trials with comprehensive searches and performed systematic reviews according to the Cochrane methods of systematical reviews.
Results:
Edaravone can reduce the rate of death or long-term disability significantly for acute ischemic stroke (AIS) (RR = 0.65; 95%CI, 0.48 to 0.89, p = 0.007). However, sensitivity analysis yielded a different result. Edaravone can also improve the short-term neurological impairment of AIS (MD = 7.09; 95%CI, 5.12 to 9.05, p < 0.00001), and ICH (MD = -4.32; 95%CI, -5.35 to -3.29, p < 0.00001).
Conclusions:
Edaravone is beneficial in improving neurological impairment resulting from AIS and ICH. However, currently there is no enough convincing evidence that edaravone reduces death or long-term disability for AIS and ICH.
Related Concept Videos
Acute Coronary Syndrome III: Diagnostic Studies
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Ischemic Stroke l: Introduction
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Hemorrhagic Stroke l: Introduction
Atherosclerosis III: Management

